<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506231</url>
  </required_header>
  <id_info>
    <org_study_id>0197-15-RMC</org_study_id>
    <nct_id>NCT02506231</nct_id>
  </id_info>
  <brief_title>The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome</brief_title>
  <official_title>The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of folinic acid (FA) -rescue following
      methotrexate (MTX) graft-versus-host disease (GVHD) prophylaxis on regimen related toxicity
      and transplantation outcomes after allogeneic hematopoietic cell transplantation (alloHCT) in
      a double blind randomized controlled trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A regimen consisted on a combination of a calcineurin inhibitor (CNI) with a short course of
      methotrexate (MTX) is the most widely used regimen for the prevention of GVHD after
      allogeneic hematopoietic cell transplantation (alloHCT). While the CNI is given in an
      adjusted dose, based on blood levels, MTX is given at a fixed 3 or 4 doses (15 mg/m2 on day
      +1, 10 mg/m2 on days +3, +6 +/- day +11). However, its use may be associated with
      considerable toxicity, including delayed engraftment, hepatotoxicity, nephrotoxicity and
      particularly oral mucositis (OM). The basis for OM is integrated: conditioning regimen and
      MTX prophylaxis for acute GVHD. OM has been shown to be associated with increased mortality
      and morbidity (principally from infection), significant pain, dysgeusia, difficulty speaking,
      difficulty receiving nutrition, hydration and oral medications, prolonged hospitalization and
      increased costs of care.

      Reducing and even omitting doses of MTX due to regimen related toxicities (mucositis, hepatic
      and renal toxicities) is common. However, dose reduction of MTX may be associated with
      increased risk of acute GVHD and early death. Several non-randomized studies have shown that
      folinic acid (FA, leucovorin) administration may reduce MTX toxicity. Nevertheless, the
      efficacy and safety of its administration remain controversial. Despite limited and
      uncontrolled data, the European Group for Blood and Marrow Transplantation (EBMT) and the
      European LeukemiaNet working group recently recommended the use of FA-rescue and proposed a
      uniform policy of FA-rescue 24h after each MTX dose: 15mg every 8h after MTX administration
      on day 1, and every 6h on days 3, 6 and 11. Yet, according to several surveys (including by
      EBMT-ELN) only half of bone marrow transplantation (BMT) centers use to give post MTX
      FA-rescue.

      The aim of this study is to assess the impact of FA-rescue following MTX GVHD prophylaxis on
      regimen related toxicity and transplantation outcomes after alloHCT in a double blind
      randomized controlled trial.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of severe (grade 3-4) oral mucositis according to the WHO scale</measure>
    <time_frame>30 days</time_frame>
    <description>According to the WHO (world health organization) oral mucositis grading scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration (in days) of severe (grade 3-4) oral mucositis according to the WHO scale</measure>
    <time_frame>30 days</time_frame>
    <description>According to the WHO (world health organization) oral mucositis grading scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of oral mucositis</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade of oral mucositis</measure>
    <time_frame>30 days</time_frame>
    <description>According to the WHO (world health organization) oral mucositis grading scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil recovery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet recovery</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to methotrexate schedule</measure>
    <time_frame>14 days</time_frame>
    <description>Number of methotrexate doses that were actually given (out of 3 doses on days 1, 3 and 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to methotrexate doses</measure>
    <time_frame>14 days</time_frame>
    <description>Actual methotrexate doses given in mg/sqm divided by scheduled doses in mg/sqm X 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of opiate use</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of total parenteral nutrition use</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of veno-occlusive disease of the liver (VOD)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of veno-occlusive disease of the liver (VOD)</measure>
    <time_frame>30 days</time_frame>
    <description>According to the Seattle criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of renal toxicity</measure>
    <time_frame>30 days</time_frame>
    <description>Creatinine &gt; 2 mg%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hepatic toxicity</measure>
    <time_frame>30 days</time_frame>
    <description>total bilirubin &gt; 2 mg%, unless mostly indirect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of febrile neutropenia</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Documented infections</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from transplantation to discharge</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of acute graft-versus-host disease</measure>
    <time_frame>100 days</time_frame>
    <description>According to the consensus grading system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of chronic graft-versus-host disease</measure>
    <time_frame>24 months</time_frame>
    <description>According to the National Institutes of Health (NIH) consensus criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Graft vs Host Disease</condition>
  <condition>Allogeneic Hematopoietic Cell Transplantation</condition>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Folinic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be randomly assigned by central randomization in a 1:1 ratio to receive folinic acid (FA) or placebo starting 24h after each MTX dose for 24h. Oral FA 15 mg/dose or placebo will be given every 8h after MTX administration on day 1 (3 doses), and every 6h (4 doses) on days 3 and 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folinic acid</intervention_name>
    <arm_group_label>Folinic acid</arm_group_label>
    <other_name>leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute leukemia in complete remission (CR) or myelodysplastic syndrome;

          -  First transplantation;

          -  Peripheral blood graft;

          -  Matched sibling or unrelated donor or one antigen or allelic mismatched sibling or
             unrelated donor (10/10 or 9/10 human leukocyte antigen match );

          -  Myeloablative or reduced intensity preparative regimen;

          -  Post-transplant GVHD prophylaxis consisting of a calcineurin inhibitor (CSA or
             tacrolimus) and methotrexate;

          -  Glutamate Pyruvate Transaminase (GPT) &lt; 3 times upper normal limit (UNL) and
             creatinine â‰¤ 1.4 mg%;

          -  Written informed consent;

        Exclusion Criteria:

          -  True non-myeloablative preparative regimen (TBI 200 +/- fludarabine);

          -  Acute leukemia not in remission;

          -  GPT &gt; 3 times upper normal limit or creatinine &gt; 1.4 mg%;

          -  Bone marrow, haploidentical or cord blood grafts;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moshe Yeshurun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moshe Yeshurun, MD</last_name>
    <phone>972-50-4065543</phone>
    <email>moshey@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liat Shargian, MD</last_name>
    <phone>972-54-2394930</phone>
    <email>LIATSHR@clalit.org.il</email>
  </overall_contact_backup>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allogeneic hematopoietic cell transplantation</keyword>
  <keyword>GVHD prophylaxis</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Folinic acid</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Mucositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

